Jed A. Latkin
2016
In 2016, Jed A. Latkin earned a total compensation of $326.2K as Chief Operating Officer and Chief Financial Officer at Navidea Biopharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $122,903 |
|---|---|
| Option Awards | $39,992 |
| Salary | $163,309 |
| Total | $326,204 |
Latkin received $163.3K in salary, accounting for 50% of the total pay in 2016.
Latkin also received $122.9K in non-equity incentive plan and $40K in option awards.
Rankings
In 2016, Jed A. Latkin's compensation ranked 12,459th out of 14,075 executives tracked by ExecPay. In other words, Latkin earned more than 11.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,459 out of 14,075 | 12th |
Division Manufacturing | 4,881 out of 5,488 | 11th |
Major group Chemicals And Allied Products | 1,734 out of 1,900 | 9th |
Industry group Drugs | 1,412 out of 1,543 | 9th |
Industry In Vitro and In Vivo Diagnostic Substances | 55 out of 65 | 15th |
Source: SEC filing on May 24, 2017.
Latkin's colleagues
We found six more compensation records of executives who worked with Jed A. Latkin at Navidea Biopharmaceuticals in 2016.
2016
Frederick Cope
Navidea Biopharmaceuticals
Chief Scientific Officer
2016
Thomas Klima
Navidea Biopharmaceuticals
Senior Vice President and Chief Commercial Officer
2016
William Regan
Navidea Biopharmaceuticals
Senior Vice President and Chief Compliance Officer
2016
Brent Larson
Navidea Biopharmaceuticals
Chief Financial Officer
2016
Michael Goldberg
Navidea Biopharmaceuticals
Chief Executive Officer
2016
Ricardo Gonzalez
Navidea Biopharmaceuticals
Chief Executive Officer
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019